These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10907968)

  • 1. Dofetilide, a new class III antiarrhythmic agent.
    Lenz TL; Hilleman DE
    Pharmacotherapy; 2000 Jul; 20(7):776-86. PubMed ID: 10907968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter.
    Lenz TL; Hilleman DE
    Drugs Today (Barc); 2000 Nov; 36(11):759-71. PubMed ID: 12845335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dofetilide: a new class III antiarrhythmic agent.
    Al-Dashti R; Sami M
    Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H; Saliba W
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS; Allen MJ; Blackburn KJ; Butrous GS; Dalrymple HW
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dofetilide: a class III-specific antiarrhythmic agent.
    Kalus JS; Mauro VF
    Ann Pharmacother; 2000 Jan; 34(1):44-56. PubMed ID: 10669186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
    Singh S; Zoble RG; Yellen L; Brodsky MA; Feld GK; Berk M; Billing CB
    Circulation; 2000 Nov; 102(19):2385-90. PubMed ID: 11067793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH; Pollak A; Singh SN; Friedrich T
    J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
    Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
    J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH; Decara JM
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dofetilide-induced long QT and torsades de pointes.
    Aktas MK; Shah AH; Akiyama T
    Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
    Saliba WI
    Cleve Clin J Med; 2001 Apr; 68(4):353-63. PubMed ID: 11326815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
    Torp-Pedersen C; Brendorp B; Køber L
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2695-704. PubMed ID: 11060831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical approach to the use and monitoring of dofetilide therapy.
    Tran A; Vichiendilokkul A; Racine E; Milad A
    Am J Health Syst Pharm; 2001 Nov; 58(21):2050-9. PubMed ID: 11715827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
    Banchs JE; Baquero GA; Nickolaus MJ; Wolbrette DL; Kelleman JJ; Samii S; Grando-Ting J; Penny-Peterson E; Davidson WR; Young SK; Naccarelli GV; Gonzalez MD
    Congenit Heart Dis; 2014; 9(3):221-7. PubMed ID: 23947935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
    N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dofetilide: a new drug to control cardiac arrhythmia.
    Elming H; Brendorp B; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Pharmacother; 2003 Jun; 4(6):973-85. PubMed ID: 12783593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.